WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013050379) GLP-1 AGONIST FOR USE IN THE TREATMENT OF STENOSIS OR/AND OBSTRUCTION IN THE PANCREATIC DUCT SYSTEM
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/050379    International Application No.:    PCT/EP2012/069485
Publication Date: 11.04.2013 International Filing Date: 02.10.2012
Chapter 2 Demand Filed:    02.08.2013    
IPC:
A61K 38/26 (2006.01), A61P 1/18 (2006.01), A61P 35/00 (2006.01)
Applicants: SANOFI-AVENTIS DEUTSCHLAND GMBH [DE/DE]; Brüningstrasse 50 65929 Frankfurt (DE)
Inventors: STECHL, Jens; (DE).
NOWOTNY, Irene; (DE).
PFEIFFER, Claudia; (DE).
PINQUIER, Jean-Louis; (FR).
MSIHID, Jerome; (FR)
Agent: WEISS, Wolfgang; Weickmann & Weickmann Postfach 860 820 81635 München (DE)
Priority Data:
11183867.8 04.10.2011 EP
Title (EN) GLP-1 AGONIST FOR USE IN THE TREATMENT OF STENOSIS OR/AND OBSTRUCTION IN THE PANCREATIC DUCT SYSTEM
(FR) AGONISTE DU GLP-1 POUR L'UTILISATION DANS LE TRAITEMENT DE LA STÉNOSE ET/OU DE L'OBSTRUCTION DANS LE SYSTÈME DES CONDUITS PANCRÉATIQUES
Abstract: front page image
(EN)The present invention relates to a pharmaceutical composition for use in the treatment of a disease or condition, wherein said disease or condition is associated with stenosis or/and obstruction located in the pancreatic duct system, said composition comprising at least one GLP-1 agonist and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance.
(FR)La présente invention concerne une composition pharmaceutique pour l'utilisation dans le traitement d'une maladie ou pathologie, ladite maladie ou pathologie étant associée à la sténose ou/et l'obstruction localisée dans le système des conduits pancréatiques, ladite composition comprenant au moins un agoniste du GLP-1 et facultativement un support, un diluant ou/et une substance auxiliaire pharmaceutiquement acceptables.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)